<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Adult naive T cells, which are at rest in normal conditions, are able to proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Adult naive T cells, which are at rest in normal conditions, are able to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Adult naive T cells, which are at rest in normal conditions, are observed to proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Adult naive T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Adult naive T cells, which are at rest in normal conditions, can proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Adult naive T cells, which are at rest in normal conditions, can proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Adult naive T cells, which are at rest in normal conditions, can strongly proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Adult naive T cells, which are at rest in normal conditions, could have proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Adult naive T cells, which are at rest in normal conditions, could have proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Adult naive T cells, which are at rest in normal conditions, could have strongly proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Adult naive T cells, which are at rest in normal conditions, have proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Adult naive T cells, which are at rest in normal conditions, have strongly proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Adult naive T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Adult naive T cells, which are at rest in normal conditions, have the ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Adult naive T cells, which are at rest in normal conditions, may proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Adult naive T cells, which are at rest in normal conditions, may proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Adult naive T cells, which are at rest in normal conditions, may strongly proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Adult naive T cells, which are at rest in normal conditions, might have proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Adult naive T cells, which are at rest in normal conditions, might have proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Adult naive T cells, which are at rest in normal conditions, might have strongly proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Adult naive T cells, which are at rest in normal conditions, proliferated strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Adult naive T cells, which are at rest in normal conditions, proliferated when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Adult naive T cells, which are at rest in normal conditions, will proliferate strongly when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Adult naive T cells, which are at rest in normal conditions, will proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Adult naive T cells, which are at rest in normal conditions, will strongly proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Cancer cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Cancer cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Cancer cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Cancer cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Cancer cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Cancer cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Cancer cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Cancer cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Cancer cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Cancer cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Cancer cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Cancer cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients are able to be found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients are able to be observed to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients are able to be proven to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients could be found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients could be observed to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients could be proven to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been found to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been found to strongly proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been observed to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been observed to strongly proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been proven to proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>Further, HIV-specific CD4+ T cells of viremic patients have been proven to strongly proliferate in response to HIV antigens when costimulation was provided by anti-CD28 antibody in vitro.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>HSC can continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>HSC can continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>HSC has continued to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>HSC has continued to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>HSC has the ability to continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>HSC has the ability to continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>HSC has the probability of continuing to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>HSC has the probability of continuing to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>HSC is able to continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>HSC is able to continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>HSC is observed to continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>HSC is observed to continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>HSC may have continued to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>HSC may have continued to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>HSC will continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>HSC will continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, are observed to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, have proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, have the ability to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, may have proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>Intrasplenically transplanted fetal liver cells, as our results have shown, will proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>Our observations illustrate that the human placenta can be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>Our observations illustrate that the human placenta can be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>Our observations illustrate that the human placenta has been endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>Our observations illustrate that the human placenta has been endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Our observations illustrate that the human placenta has the ability to be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Our observations illustrate that the human placenta has the ability to be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Our observations illustrate that the human placenta is able to be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Our observations illustrate that the human placenta is able to be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Our observations illustrate that the human placenta is shown to be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Our observations illustrate that the human placenta is shown to be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Our observations illustrate that the human placenta may have been endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Our observations illustrate that the human placenta may have been endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Our observations illustrate that the human placenta was endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Our observations illustrate that the human placenta was endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Our observations illustrate that the human placenta will be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Our observations illustrate that the human placenta will be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Stat5ab-/-peripheral T cells are able to regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Stat5ab-/-peripheral T cells are able to regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Stat5ab-/-peripheral T cells are observed to regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Stat5ab-/-peripheral T cells are observed to regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Stat5ab-/-peripheral T cells can regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Stat5ab-/-peripheral T cells have regained the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Stat5ab-/-peripheral T cells have regained the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Stat5ab-/-peripheral T cells have the probability of regaining the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Stat5ab-/-peripheral T cells have the probability of regaining the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>Stat5ab-/-peripheral T cells may have regained the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>The ability of EBD cells being able to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>The ability of EBD cells being able to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>The ability of EBD cells being observed to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>The ability of EBD cells being observed to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>The ability of EBD cells having proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>The ability of EBD cells having strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>The ability of EBD cells having the ability to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>The ability of EBD cells having the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>The ability of EBD cells proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>The ability of EBD cells that can proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>The ability of EBD cells that have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>The ability of EBD cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>The ability of EBD cells that have the ability to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>The ability of EBD cells that have the ability to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>The ability of EBD cells that is able to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>The ability of EBD cells that is able to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>The ability of EBD cells that is observed to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>The ability of EBD cells that is observed to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>The ability of EBD cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>The ability of EBD cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>The ability of EBD cells that may proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>The ability of EBD cells that may proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>The ability of EBD cells that will proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>The ability of EBD cells that will proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>These results show that intrasplenically transplanted fetal liver cells are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>These results show that intrasplenically transplanted fetal liver cells are observed to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>These results show that intrasplenically transplanted fetal liver cells have proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>These results show that intrasplenically transplanted fetal liver cells have the ability to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>These results show that intrasplenically transplanted fetal liver cells may have proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>These results show that intrasplenically transplanted fetal liver cells proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>These results show that intrasplenically transplanted fetal liver cells will proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
